Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Rheumatology (Oxford) ; 59(4): 869-878, 2020 04 01.
Artigo em Inglês | MEDLINE | ID: mdl-31497857

RESUMO

OBJECTIVES: Fatty acid oxidation (FAO) and glycolysis have been implicated in immune regulation and activation of macrophages. However, investigation of human monocyte intracellular metabolism in the context of the hypoxic and inflammatory rheumatoid arthritis (RA) synovium is lacking. We hypothesized that exposure of monocytes to the hypoxic and inflammatory RA environment would have a profound impact on their metabolic state, and potential to contribute to disease pathology. METHODS: Human monocytes were isolated from buffy coats and exposed to hypoxia. Metabolic profiling of monocytes was carried out by LC-MS metabolomics. Inflammatory mediator release after LPS or RA-synovial fluid (RA-SF) stimulation was analysed by ELISA. FAO was inhibited by etomoxir or enhanced with exogenous carnitine supplementation. Transcriptomics of RA blood monocytes and RA-SF macrophages was carried out by microarray. RESULTS: Hypoxia exacerbated monocyte-derived CCL20 and IL-1ß release in response to LPS, and increased glycolytic intermediates at the expense of carnitines. Modulation of carnitine identified a novel role for FAO in the production of CCL20 in response to LPS. Transcriptional analysis of RA blood monocytes and RA-SF macrophages revealed that fatty acid metabolism was altered and CCL20 increased when monocytes enter the synovial environment. In vitro analysis of monocytes showed that RA-SF increases carnitine abundance and CCL20 production in hypoxia, which was exacerbated by exogenous carnitine. CONCLUSION: This work has revealed a novel inflammatory mechanism in RA that links FAO to CCL20 production in human monocytes, which could subsequently contribute to RA disease pathogenesis by promoting the recruitment of Th17 cells and osteoclastogenesis.


Assuntos
Artrite Reumatoide/metabolismo , Microambiente Celular , Quimiocina CCL20/metabolismo , Ácidos Graxos/metabolismo , Hipóxia/metabolismo , Monócitos/metabolismo , Líquido Sinovial , Carnitina/farmacologia , Quimiocina CCL20/efeitos dos fármacos , Cromatografia Líquida , Inibidores Enzimáticos/farmacologia , Compostos de Epóxi/farmacologia , Perfilação da Expressão Gênica , Humanos , Técnicas In Vitro , Lipopolissacarídeos/farmacologia , Espectrometria de Massas , Metabolômica , Análise em Microsséries , Monócitos/efeitos dos fármacos , Membrana Sinovial/metabolismo
2.
Inflammation ; 39(3): 1124-9, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27072015

RESUMO

Shikonin, which is derived from Lithospermum erythrorhizon, a herb used in traditional medicine, has long been considered to be a useful treatment for various diseases in traditional oriental medicine. Shikonin has recently been reported to have several pharmacological properties, e.g., it has anti-microbial, anti-tumor, and anti-inflammatory effects. The aim of this study was to examine whether shikonin is able to influence the production of interleukin (IL)-6, IL-8, and/or chemokine C-C motif ligand (CCL)20, which contribute to the pathogenesis of periodontal disease, in human periodontal ligament cells (HPDLC). The production levels of IL-6, IL-8, and CCL20 in HPDLC were determined using an ELISA. Western blot analysis was used to detect nuclear factor kappa B (NF-κB) pathway activation in HPDLC. Shikonin prevented IL-1ß- or tumor necrosis factor (TNF)-α-mediated IL-6, IL-8, and CCL20 production in HPDLC. Moreover, we found that shikonin suppressed the phosphorylation and degradation of inhibitor of kappa B-alpha (IκB-α) in IL-1ß- or TNF-α-stimulated HPDLC. These findings suggest that shikonin could have direct beneficial effects against periodontal disease by reducing IL-6, IL-8, and CCL20 production in periodontal lesions.


Assuntos
Citocinas/efeitos dos fármacos , Naftoquinonas/farmacologia , Ligamento Periodontal/citologia , Anti-Inflamatórios não Esteroides/farmacologia , Células Cultivadas , Quimiocina CCL20/biossíntese , Quimiocina CCL20/efeitos dos fármacos , Citocinas/biossíntese , Humanos , Inflamação , Interleucina-6/antagonistas & inibidores , Interleucina-6/biossíntese , Interleucina-8/biossíntese , Interleucina-8/efeitos dos fármacos , Doenças Periodontais/tratamento farmacológico , Doenças Periodontais/patologia , Ligamento Periodontal/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA